Immedica Pharma AB

We're expanding! Immedica is looking for a Drug Safety Associate to join our Global Drug Safety team. If you're ready to grow with a fast-moving company and make a real impact in patients´ lives, this could be the perfect role for you. Apply today! https://lnkd.in/esyW_Snu #DrugSafety #PharmaCareers #PatientSafety #ImmedicaPharma

We’re thrilled to welcome Joe Whalen to Immedica’s business development team! Joe brings a wealth of expertise in strategic transactions and will focus on driving business development initiatives in the U.S. as we continue to expand our presence in rare diseases and specialty care. Welcome aboard, Joe! Read more here: https://lnkd.in/eWZcU7ZK #BusinessDevelopment #ImmedicaPharma #RareDiseases #HealthcareGrowth

We are pleased to announce the completion of Immedica´s joint acquisition by KKR and Impilo. This partnership marks an exciting step forward in our growth journey, enabling us to continue delivering innovative treatments to patients with rare diseases. With the support of our new partners, we are looking forward to expanding our reach and enhancing our portfolio to meet high unmet medical needs. Read more here: https://lnkd.in/emhqg6j8 #ImmedicaPharma #GrowthJourney #HealthcarePartnership

Join Immedica's growing team! We are looking for a Global Regulatory Manager - CMC specialist to join our expanding Regulatory Affairs team at Immedica. If you're experienced in pharmaceutical regulatory affairs, passionate about making a difference in rare diseases, and eager to grow with a dynamic Swedish company, we want to hear from you! Read more about the position here: https://lnkd.in/esyW_Snu #JobOpening #RegulatoryAffairs #Pharmaceuticals #ImmedicaPharma #RareDiseases

Exciting news! Immedica is expanding its presence in the U.S. with a new Chicago-based commercial business, strengthening its commitment to providing treatments for patients with rare diseases. Additionally, Daniel Camardo has been appointed as President of Immedica North America, bringing vast experience to lead the growth in this region. This strategic move highlights Immedica's dedication to improving patient outcomes across the globe. Read more on www.immedica.com. #RareDisease #HealthcareExpansion #Leadership

Many people are unaware of the rare disorder called arginase deficiency (ARG1-D), which can lead to severe symptoms like spasticity, seizures, and developmental delays if not diagnosed early. Misdiagnosis is common due to its similarity to conditions like cerebral palsy. Raising awareness is crucial for timely diagnosis and treatment to prevent irreversible damage. Learn more about how early detection through simple blood tests can make a difference in patient outcomes. (Article in Swedish) https://lnkd.in/eGYKNP6q #RareDiseaseAwareness #Arginase1Deficiency #EarlyDiagnosis

Immedica will be present at the SSIEM Annual Symposium from September 3-6 in Porto, Portugal. Come visit us at Booth S13 to learn more about how we are making a difference in the lives of people with genetic and metabolic diseases. Let’s connect and discuss how we can collaborate to advance care for those with unmet medical needs. See you in Porto! #SSIEM2024 #RareDiseases #MetabolicDiseases #Immedica

Exciting Opportunity at Immedica! We are thrilled to announce an opening for the role of Brand Lead, Genetic and Metabolic Diseases. This is a unique opportunity to lead a major EU launch and play a pivotal role in expanding our presence in the genetic and metabolic disease area. As the International Brand Lead, you will drive brand strategies, collaborate with cross-functional teams, and ensure the successful introduction of our latest treatment across Europe. If you are a proactive leader with a passion for rare diseases and thrive in a dynamic environment, this could be the perfect fit for you. For more details about the role and how to apply, go to www.immedica.com/careers. Join us in making a difference for patients with rare diseases!

At Immedica, our platform empowers us to serve patients in more than 50 countries. With extensive experience in the commercialization of rare disease and specialty care products across Europe and the MENA region, our global distribution network ensures we reach those who need it most. Our comprehensive capabilities cover marketing, sales, and market access, supported by a skilled rare disease field force. We manage complex pricing, reimbursement, tender processes, and regulatory affairs, always upholding the highest standards of compliance and quality assurance. Want to know how these capabilities translate into real-world success? Our General Managers for DACH, UK & Ireland, and France & Benelux share their key achievements from 2023 and insights on how we continue to advance patient care. Dive into these interviews and more in Immedica's 2023 Annual Report. Read more here: https://lnkd.in/eiucDHUa #Immedica #HealthcareExcellence #GlobalReach #RareDiseases 

Did you know that 350 million people globally are living with rare diseases? These conditions, affecting 1 in 10 people, present unique challenges not only for patients but also for their families, healthcare professionals, and society at large. With over 6,000 identified rare diseases, there is a high unmet need for research, diagnosis, and support. Patient identification is critical, as it can take an average of 8 years to receive an accurate diagnosis. Limited treatment options, high development costs, and isolated patient communities further complicate care. Yet, progress is being made through collaboration among patient organizations, healthcare professionals, and advocacy groups. Learn more about rare diseases on www.immedica.com #RareDiseases #Immedica #ImmedicaPharma